Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivi...
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in comb...
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Conditions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 1037352
- Registration Number
- NCT02893371
- Locations
- 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
- Conditions
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT02845453
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD
- Conditions
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Duke University
- Target Recruit Count
- 60
- Registration Number
- NCT02720198
- Locations
- 🇺🇸
Institute for Advanced Medical Research, Alpharetta, Georgia, United States
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Shanxi Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT02650102
- Locations
- 🇨🇳
First Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi, China
Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2015-11-24
- Target Recruit Count
- 82
- Registration Number
- NCT02612948
- Locations
- 🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
- Conditions
- Interventions
- Other: Caregiver psycho-education and skills trainingOther: Caregiver support available at the study siteDrug: Paliperidone palmitateDrug: ChlorpromazineDrug: DroperidolDrug: FluphenazineDrug: HaloperidolDrug: LoxapineDrug: PerphenazineDrug: PimozideDrug: ProchlorperazineDrug: ThiothixeneDrug: ThioridazineDrug: TrifluoperazineDrug: AripiprazoleDrug: AsenapineDrug: ClozapineDrug: IloperidoneDrug: OlanzapineDrug: PaliperidoneDrug: QuetiapineDrug: RisperidoneDrug: Ziprasidone
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 296
- Registration Number
- NCT02600741
Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder
- Conditions
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 54
- Registration Number
- NCT02562287
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
- Conditions
- Interventions
- First Posted Date
- 2015-08-27
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Fundación Marques de Valdecilla
- Target Recruit Count
- 136
- Registration Number
- NCT02534363
- Locations
- 🇪🇸
University Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up
- Conditions
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Fundación Marques de Valdecilla
- Target Recruit Count
- 203
- Registration Number
- NCT02526030
- Locations
- 🇪🇸
University Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT02462473
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.